Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management

Kalkan, Göknur

doi:10.4274/turkderm.09476

Cited by 7 publications

(3 citation statements)

References 67 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, it has been known that psoriasis is no longer limited to the skin, but is associated with cardiovascular diseases, metabolic syndrome, and obesity (25). In studies, GDF-15 was detected in high concentrations in metabolic syndrome, diabetes mellitus and cardiovascular diseases, which are comorbidities accompanying psoriasis, and it was evaluated as a new inflammatory marker and also seen as a treatment target (6,12,(14)(15)(16)(17)(18).…”

Section: Süleyman Demirel üNiversitesi Tıp Fakültesi Dergisimentioning

confidence: 99%

Could Growth Differentiation Factor-15 Be a New Inflammatory Pathway in Psoriasis Vulgaris?

Korkmaz

Şirin

Ayvaz

et al. 2022

SDÜ Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

Objective: Psoriasis vulgaris is a chronic inflammatory disease, in which T cells play an important role in the etiopathogenesis and inflammatory mechanisms. Growth differentiation factor (GDF) 15 is a member of the transforming growth factor beta superfamily (TGF-ß), which increases with inflammation and has various cell regulatory functions. In this study; It was aimed to evaluate the relationship between serum GDF-15 level and Tumor necrosis factor alpha (TNF-α), which is thought to have a role in the etiopathogenesis of the disease, and other metabolic parameters. Materials and methods: Forty-one patients with psoriasis vulgaris and 41 healthy controls were included in the study. Dermatological examination of all patients was performed and PASI score was calculated. Height and weight measurements, systolic and diastolic blood pressures, waist and hip circumferences, lipid profiles, and biochemical parameters of the patients were evaluated. Serum GDF-15 and TNF-α levels were measured by ELISA method. Results: There was no significant difference between the patient and control groups in terms of age, gender, lipid profiles, biochemical parameters and hs-CRP levels. Serum GDF-15 and TNF-α levels were found to be significantly higher in the patient group compared to the control group (p

show abstract

Section: Süleyman Demirel üNiversitesi Tıp Fakültesi Dergisimentioning

confidence: 99%

Could Growth Differentiation Factor-15 Be a New Inflammatory Pathway in Psoriasis Vulgaris?

Korkmaz

Şirin

Ayvaz

et al. 2022

SDÜ Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

show abstract

“…Other comorbidities include metabolic syndrome, hypertension, dyslipidemia, atherosclerotic diseases, ocular findings (uveitis), inflammatory bowel diseases, and non-alcoholic fatty liver disease. Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea syndrome (OSAS) are rarer comorbidities (2). The number of studies investigating the prevalence of OSAS in psoriasis patients is limited.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Obstructive Sleep Apnea Syndrome in Psoriasis Patients

Karagün

Balbay

2019

Düzce Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

Aim: Psoriasis is a frequently seen chronic systemic inflammatory disease accompanied by several comorbid conditions that affects 2-3% of the general population. One of the comorbidities rarely accompanying psoriasis is obstructive sleep apnea syndrome (OSAS). OSAS is a disease characterized by recurrent complete (apnea) or partial (hypopnea) upper airway obstruction episodes and frequently by decreased blood oxygen saturation. The purpose of this study was to evaluate the risk factors for OSAS by investigating OSAS symptoms in psoriasis patients. Material and Methods: Eighty-two patients aged over 16, diagnosed with psoriasis, and under follow-up by the Duzce University Medical of Faculty, Dermatology and Venereal Diseases Polyclinic, Turkey, were included in the study. Patients' OSAS symptoms were investigated. The Epworth Sleepiness Scale was used to assess excessive daytime somnolence. Results: Of the patients 51.2% (n=42) were male and 48.8% (n=40) female. Patients' mean age was 47.09±14.10 years. Patients' mean time of psoriasis diagnosis was 16.97±10.55 years, and mean Psoriatic Area Severity Index (PASI) score was 11.25±6.32. Severe disease was present in 54.9% of patients (n=45) based on PASI classification. Prevalence of 56.1% for snoring, 25.6% for excessive daytime sleepiness, and 15.9% for witnessed apnea were determined in these patients. Forty-seven (57.3%) cases had at least one major symptom. The most common minor symptoms were inability to sleep with 25.6% (n=21) and insufficient disrupted sleep with 22.0% (n=18). Conclusion: Prevalence of OSAS symptoms in psoriasis patients were found high. Psoriasis patients with OSAS symptoms must be referred to relevant specialists for polysomnographic evaluation.

show abstract

“…P soriasis vulgaris (PV) was thought to be a limited, chronic, and recurrent skin disease in the past, whereas it has been considered as a systemic inflammatory disease in recent years [1] . Its most characteristic lesions are often chronic, sharply limited, vivid red, and pearlescent white squamous plaques.…”

mentioning

confidence: 99%

Serum Lipoprotein(a) and Lipid Levels in Patients with Chronic Plaque Type Psoriasis

Kayıran¹

2018

Haydarpasa Numune Med J

View full text Add to dashboard Cite

Introduction: Psoriasis vulgaris (PV) was considered to be a chronic, recurrent skin disease, but it has been accepted as a chronic systemic inflammatory disease in recent years. Lipoprotein(a) (Lp(a)) is a lipoprotein that is synthesized in the liver and has a low-density lipoprotein (LDL)-like molecular structure consisting of phospholipids, cholesterol, and apolipoprotein B-100 derivative. Serum levels of Lp(a) are not affected by the amount of lipid incorporated into the diet and lifestyle changes. The aim of this study is to compare blood lipid and Lp(a) levels between the PV patient group and healthy control group and to investigate whether psoriasis creates a predisposition to atherosclerosis. Methods: Forty-four patients with clinical and/or histopathological diagnosis of chronic plaque-type PV and 48 healthy subjects were included in the study. Serum total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, serum LDL cholesterol, very low-density lipoprotein (VLDL) cholesterol, and serum Lp(a) levels were measured. Results: Total cholesterol, triglyceride, and HDL, LDL, and VLDL cholesterol levels were not statistically different between the psoriasis and healthy control groups (p=0.071, p=0.374, p=0.060, p=0.421, and p=0.759, respectively). Lp(a) levels were higher in the psoriasis group than in the healthy control group (p<0.001). Discussion and Conclusion: According to the results of our study, increased Lp(a) levels in patients with psoriasis may be more likely to induce atherosclerosis than those in the normal population. On the other hand, the identification of the Lp(a) level in patients with psoriasis with cardiovascular diseases may be an appropriate diagnostic tool for the evaluation of atherosclerotic and vasoocclusive pathologies.

show abstract

Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management

Cited by 7 publications

References 67 publications

Could Growth Differentiation Factor-15 Be a New Inflammatory Pathway in Psoriasis Vulgaris?

Could Growth Differentiation Factor-15 Be a New Inflammatory Pathway in Psoriasis Vulgaris?

Prevalence of Obstructive Sleep Apnea Syndrome in Psoriasis Patients

Serum Lipoprotein(a) and Lipid Levels in Patients with Chronic Plaque Type Psoriasis

Contact Info

Product

Resources

About